New Human CD22/Siglec‐2 Ligands with a Triazole Glycoside
Sign Up to like & getrecommendations! Published in 2017 at "ChemBioChem"
DOI: 10.1002/cbic.201600707
Abstract: CD22 is a member of the Siglec family. Considerable attention has been drawn to the design and synthesis of new Siglec ligands to explore target biology and innovative therapies. In particular, CD22‐ligand‐targeted nanoparticles with therapeutic… read more here.
Keywords: new human; human cd22; cd22; cd22 siglec ... See more keywords
Conformationally Constrained Sialyl Analogues as New Potential Binders of h‐CD22
Sign Up to like & getrecommendations! Published in 2022 at "Chembiochem"
DOI: 10.1002/cbic.202200076
Abstract: Here, two conformationally constrained sialyl analogues were synthesized and characterized in their interaction with the inhibitory Siglec, human CD22 (h‐CD22). An orthogonal approach, including biophysical assays (SPR and fluorescence), ligand‐based NMR techniques, and molecular modelling,… read more here.
Keywords: cd22; analogues new; conformationally constrained; sialyl analogues ... See more keywords
Upregulation of CD22 by Chidamide promotes CAR T cells functionality
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-00227-4
Abstract: Treatment failure or relapse due to tumor escape caused by reduction in target antigen expression has become a challenge in the field of CART therapy. Target antigen density is closely related to the effectiveness of… read more here.
Keywords: cart; cd22; target; expression ... See more keywords
Engineering Novel CD19/CD22 Dual-Target CAR-T Cells for Improved Anti-Tumor Activity.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer investigation"
DOI: 10.1080/07357907.2021.2005798
Abstract: Despite high remission rates following CAR-T cell therapy in B-ALL, relapse due to loss of the targeted antigen is increasingly recognized as a mechanism of immune escape. We hypothesized that simultaneous targeting of CD19 and… read more here.
Keywords: cd19 cd22; cd22; car; anti tumor ... See more keywords
Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B‐acute lymphoblastic leukaemia
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.16949
Abstract: Relapsed B-acute lymphoblastic leukaemia (B-ALL) remains a difficult disease to treat and is associated with a poor prognosis. Antibody-based immunotherapy (blinatumomab), antibody-drug conjugates [inotuzumab ozogamicin (InO)] and cellular immunotherapies [chimeric antigen receptor T cells (CAR-T)]… read more here.
Keywords: cd22; ino; lymphoblastic leukaemia; truncating mutation ... See more keywords
Characterization of the immune regulatory property of CD22+ CD9+ B cells
Sign Up to like & getrecommendations! Published in 2022 at "Immunology"
DOI: 10.1111/imm.13539
Abstract: Immunodisruptive homeostasis is recognized in allergic disorders. The mechanism of restoration of immunologic homeostasis in the body is not fully understood. Galectin‐9 (Gal9) and CD22 have immune regulatory functions. The goal of this study is… read more here.
Keywords: cd22; b10 cells; cd22 cd9; immune regulatory ... See more keywords
The inhibitory coreceptor CD22 restores B cell signaling by developmentally regulating Cd45−/− immunodeficient B cells
Sign Up to like & getrecommendations! Published in 2022 at "Science Signaling"
DOI: 10.1126/scisignal.abf9570
Abstract: The protein tyrosine phosphatase CD45 plays a crucial role in B cell antigen receptor (BCR) signaling by activating Src family kinases. Cd45−/− mice show altered B cell development and a phenotype likely due to reduced… read more here.
Keywords: cd22; cell; bcr ligation; cd45 cells ... See more keywords
Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope
Sign Up to like & getrecommendations! Published in 2020 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2020-000896
Abstract: Background There are few therapeutic options available for patients with B-cell acute lymphoblastic leukemia (B-ALL) relapsing as CD19– either after chemotherapy or CD19-targeted immunotherapies. CD22-chimeric antigen receptor (CAR) T cells represent an attractive addition to… read more here.
Keywords: cd19; hcd22; cd22; membrane distal ... See more keywords
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-2399
Abstract: Purpose: We assessed the relationship between cluster of differentiation-22 (CD22) expression and outcomes of inotuzumab ozogamicin versus standard of care (SC) in INO-VATE (NCT01564784). Patients and Methods: Adults with relapsed/refractory B-cell precursor CD22-positive (by local… read more here.
Keywords: ozogamicin versus; cd22 positivity; inotuzumab ozogamicin; cd22 ... See more keywords
Abstract 3763: UCART22: allogenic adoptive immunotherapy of leukemia by targeting CD22 with CAR T-cells
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-3763
Abstract: Adoptive immunotherapy using autologous T-cells endowed with chimeric antigen receptors (CARs) has given rise to long-term durable remissions and remarkable objective response rates in patients with refractory leukemia, raising hopes that a wider application of… read more here.
Keywords: adoptive immunotherapy; cd22; targeting cd22; cd22 car ... See more keywords
Study of AUTO3, the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22, Followed By Anti-PD1 Consolidation in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Alexander Study
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-119197
Abstract: Introduction CAR T-cell therapies directed against CD19 have shown significant activity in patients with r/r DLBCL; however, a significant number of patients relapse due to target antigen loss or upregulation of PDL1. In this study,… read more here.
Keywords: consultancy honoraria; cd22; study; cell ... See more keywords